Tetanus
📧 Sign up to get email alerts when something new happens for Tetanus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-01-04Clinical Trial Update: Regulatory Post-Marketing Surveillance Study for TETRAXIM™ [Phase 4]
Phase 4 post-marketing surveillance study for TETRAXIM. The trial completed and results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2016-12-29Clinical Trial Update: Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ [Phase 4]
Phase 4 study assessing antibody persistence in children previously vaccinated with Infanrix Hexa or Infanrix-IPV/Hib; completed with result…
-
CLINICAL_TRIALS trial_result · 2016-12-12Clinical Trial Update: Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children [Phase 3]
Phase 3 trial update assessing safety of a booster dose of Boostrix vaccine in healthy Vietnamese children; results posted in 2016. Conditio…
-
CLINICAL_TRIALS trial_result · 2016-11-30Clinical Trial Update: Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants [Phase 4]
Phase 4 trial update on immunogenicity and safety of Infanrix Hexa in infants, with results posted after completion.
-
CLINICAL_TRIALS trial_result · 2016-11-21Clinical Trial Update: Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents [Phase 3]
Phase 3 study of BK1301 DTaP vaccine booster in adolescents completed; results have been posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2016-11-07Clinical Trial Update: Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine [Phase 1, Phase 2]
A Phase 1/2 safety and immunogenicity study of a tetanus, diphtheria, and acellular pertussis (Tdap) vaccine developed by Green Cross Corpor…
-
CLINICAL_TRIALS trial_result · 2016-11-04Clinical Trial Update: Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age [Phase 2]
Phase 2 trial update evaluating the immunogenicity and safety of a pentavalent DTPa-HBV-IPV/Hib vaccine given at 2, 3, and 4 months of age.
-
CLINICAL_TRIALS trial_result · 2016-10-28Clinical Trial Update: Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine [Phase 3]
A Phase 3 trial comparing GSK Boostrix (dTpa) with a Chinese diphtheria-tetanus vaccine to assess safety and immunogenicity.
-
CLINICAL_TRIALS trial_result · 2016-10-27Clinical Trial Update: Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age. [Phase 3]
A Phase 3 trial assessing the safety and reactogenicity of GSK's dTpa vaccine Boostrix when given to children aged 6-8 years; the study has …
-
CLINICAL_TRIALS trial_result · 2016-10-12Clinical Trial Update: Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age [Phase 3]
A Phase 3 study assessing the safety and reactogenicity of GlaxoSmithKline's DTPa/Hib vaccine administered at 3, 4, and 5 months of age has …
-
CLINICAL_TRIALS trial_result · 2016-10-12Clinical Trial Update: Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants [Phase 3]
GlaxoSmithKline completed a Phase 3 trial comparing immunogenicity and safety of two formulations of the DTPa-HBV-IPV/Hib vaccine in healthy…
-
CLINICAL_TRIALS trial_result · 2016-10-07Clinical Trial Update: Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants [Phase 3]
The document reports Phase 3 results evaluating lot-to-lot consistency of Tritanrix-HepB/Hib-MenAC and its non-inferiority compared with Tri…
-
CLINICAL_TRIALS trial_result · 2016-10-07Clinical Trial Update: Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age. [Phase 3]
A Phase 3 immunization and safety study comparing two formulations of DTPw-HBV/HIB given at birth with Hepatitis B at 2, 4, and 6 months was…
-
CLINICAL_TRIALS trial_result · 2016-09-28Clinical Trial Update: Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules [Phase 3]
Phase 3 trial evaluating immunogenicity and safety of GlaxoSmithKline's pentavalent DTPa-HBV-IPV/Hib vaccine in Indian infants across two va…
-
CLINICAL_TRIALS trial_result · 2016-09-28Clinical Trial Update: Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib [Phase 3]
Phase 3 booster study evaluating immunogenicity, reactogenicity, and safety of GSK's DTPw-HBV/Hib vaccine booster compared with the standard…
-
CLINICAL_TRIALS trial_result · 2016-09-23Clinical Trial Update: Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 [Phase 2]
Phase 2 clinical trial update evaluating a booster dose of GlaxoSmithKline's 10-valent pneumococcal conjugate vaccine and a single dose of t…
-
CLINICAL_TRIALS trial_result · 2016-09-21Clinical Trial Update: Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth [Phase 3]
This Phase 3 trial evaluated and compared the immune responses to two DTP-containing vaccines (Tritanrix-HepB/Hib-MenAC vs Tritanrix-HepB/Hi…
-
CLINICAL_TRIALS trial_result · 2016-09-20Clinical Trial Update: Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose. [Phase 3]
A Phase 3 immunogenicity and safety study of an infant meningitis vaccine given after a hepatitis B birth dose completed; the trial evaluate…
-
CLINICAL_TRIALS trial_result · 2016-09-16Clinical Trial Update: Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants [Phase 3]
This Phase 3 trial in healthy infants evaluated whether giving Tritanrix-HepB/Hib-MenAC with a birth-dose Hepatitis B vaccine yields an immu…
-
CLINICAL_TRIALS trial_result · 2016-09-15Clinical Trial Update: Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety [Phase 2]
Phase 2 trial comparing GSK's DTaP-IPV candidate vaccine with separately administered DTaP and IPV vaccines to assess immune response and sa…
-
CLINICAL_TRIALS trial_result · 2016-09-15Clinical Trial Update: Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine. [Phase 3]
Phase 3 results evaluating a GSK Tdap booster vaccine candidate for immunogenicity and safety in children and adolescents previously given f…
-
CLINICAL_TRIALS trial_result · 2016-09-15Clinical Trial Update: Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) [Phase 4]
Phase 4 immunogenicity and reactogenicity study of Boostrix and Boostrix-IPV has completed.
-
CLINICAL_TRIALS trial_result · 2016-09-09Clinical Trial Update: A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. [Phase 2]
Phase 2 trial by GlaxoSmithKline evaluated antibody persistence and booster response, as well as safety, in individuals previously primed wi…
-
CLINICAL_TRIALS trial_result · 2016-09-09Clinical Trial Update: A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine [Phase 3]
Phase 3 trial comparing a combined Tdap booster to a licensed Td vaccine has completed, assessing protection against diphtheria, tetanus, an…
-
CLINICAL_TRIALS trial_result · 2016-09-07Clinical Trial Update: Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis® [Phase 3]
Phase 3 trial comparing GlaxoSmithKline's reduced antigen DTaP-IPV vaccine to Boostrix and standalone or Revaxis-administered IPV in tetanus…